^
Association details:
| Biomarker: | CDK12 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide.
Published date:
02/13/2023
Excerpt:
African Americans with CRPC post treatment with abiraterone and/or enzalutamide had a higher frequency of P/LP CDK12 and KIT mutations, which have both been shown to lead to aggressive clinical features and treatment resistance.
DOI:
10.1200/JCO.2023.41.6_suppl.35
Source:
Title:
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study
Published date:
05/14/2021
Excerpt:
In multivariate Cox regression analysis, a CDK12 defect was significantly associated with inferior PFS after abiraterone treatment.
DOI:
10.6004/jnccn.2020.7663
Source:
Title:
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Published date:
04/21/2020
Excerpt:
Of those who received first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer (mCRPC; n = 34), 41.2% had a PSA response, and median PFS was 5.3 months….CDK12-altered prostate cancer is an aggressive subtype with poor outcomes to hormonal and taxane therapies as well as to PARP inhibitors.
DOI:
10.1200/po.19.00399
Source:
Title:
Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.
Published date:
02/13/2020
Excerpt:
The patients with CDK12 defect showed rapid resistance to abiraterone and limited efficacy of PARPi.
Source:
Title:
Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.
Published date:
05/28/2020
Excerpt:
AR amplification and TP53 or RB1 defect were associated with resistance to abiraterone or docetaxel. CDK12 was more frequently altered in our cohort than those in previous reports which mainly focused on Caucasian population. The patients with CDK12 defect showed rapid resistance to abiraterone and limited efficacy of Poly (ADP-ribose) polymerase inhibitors (PARPi). However, these patients seemed to benefit from chemotherapy, especially platinum-based chemotherapy.
DOI:
10.1200/JCO.2020.38.15_suppl.e17556
